PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33665638-1 2021 The aberrant expression of dopamine receptors (DRDs) in acute myeloid leukemia (AML) cells has encouraged the repurposing of DRD antagonists such as thioridazine (TDZ) as anti-leukemic agents. Thioridazine 149-161 dopamine receptor D2 Homo sapiens 47-50 33665638-1 2021 The aberrant expression of dopamine receptors (DRDs) in acute myeloid leukemia (AML) cells has encouraged the repurposing of DRD antagonists such as thioridazine (TDZ) as anti-leukemic agents. Thioridazine 163-166 dopamine receptor D2 Homo sapiens 47-50 31822725-1 2019 Several recent publications demonstrated that DRD2-targeting antipsychotics such as thioridazine induce proliferation arrest and apoptosis in diverse cancer cell types including those derived from brain, lung, colon, and breast. Thioridazine 84-96 dopamine receptor D2 Homo sapiens 46-50 31645049-10 2020 RESULTS: D2R antagonists thioridazine, pimozide, haloperidol, and remoxipride decrease spheroid formation behaviors at a selective 100 nmol/L concentration, while D2R agonists PHNO, sumanirole, and ropinirole increase the formation of spheroids. Thioridazine 25-37 dopamine receptor D2 Homo sapiens 9-12 31645049-10 2020 RESULTS: D2R antagonists thioridazine, pimozide, haloperidol, and remoxipride decrease spheroid formation behaviors at a selective 100 nmol/L concentration, while D2R agonists PHNO, sumanirole, and ropinirole increase the formation of spheroids. Thioridazine 25-37 dopamine receptor D2 Homo sapiens 163-166 31822725-4 2019 Further, DRD2 stimulation with quinpirole, a DRD2 agonist, promotes self-renewal, even in cell lines in which thioridazine does not inhibit self-renewal. Thioridazine 110-122 dopamine receptor D2 Homo sapiens 9-13 28649130-1 2017 Recent evidence shows that dopamine D2-like receptor (D2DR) antagonists, such as trifluoperazine and thioridazine, are effective for cancer therapy and inhibition of cancer stem-like cells (CSCs). Thioridazine 101-113 dopamine receptor D2 Homo sapiens 54-58 30131338-0 2018 Thioridazine inhibits self-renewal in breast cancer cells via DRD2-dependent STAT3 inhibition, but induces a G1 arrest independent of DRD2. Thioridazine 0-12 dopamine receptor D2 Homo sapiens 62-66 30131338-4 2018 The inhibition of self-renewal by thioridazine in these cells is mediated by DRD2 inhibition. Thioridazine 34-46 dopamine receptor D2 Homo sapiens 77-81 30816566-13 2019 Binding to DRD2 or DRD4 might have mediated the action of thioridazine involved in the differentiation of CSC-like cells. Thioridazine 58-70 dopamine receptor D2 Homo sapiens 11-15 30093531-1 2018 We completed a phase 1 dose-escalation trial to evaluate the safety of a dopamine receptor D2 (DRD2) antagonist thioridazine (TDZ), in combination with cytarabine. Thioridazine 112-124 dopamine receptor D2 Homo sapiens 73-93 30093531-1 2018 We completed a phase 1 dose-escalation trial to evaluate the safety of a dopamine receptor D2 (DRD2) antagonist thioridazine (TDZ), in combination with cytarabine. Thioridazine 112-124 dopamine receptor D2 Homo sapiens 95-99 30093531-1 2018 We completed a phase 1 dose-escalation trial to evaluate the safety of a dopamine receptor D2 (DRD2) antagonist thioridazine (TDZ), in combination with cytarabine. Thioridazine 126-129 dopamine receptor D2 Homo sapiens 95-99 28454238-6 2017 The effect of the DRD2 antagonist, thioridazine, on the proliferation of the AGS gastric cancer cells was determined. Thioridazine 35-47 dopamine receptor D2 Homo sapiens 18-22 28454238-10 2017 Furthermore, the DRD2 antagonist, thioridazine, inhibited the growth of AGS gastric cancer cells. Thioridazine 34-46 dopamine receptor D2 Homo sapiens 17-21 8302284-1 1994 P-type Ca2+ channels in cerebellar Purkinje neurons and N-type Ca2+ channels in sympathetic neurons were found to be inhibited by D2 dopamine receptor antagonists with diverse structures, including phenothiazines (chlorpromazine and thioridazine), diphenylbutylpiperidines (fluspirilene and pimozide), butyrophenones (haloperidol and spiperone), and a piperazine (fluphenazine). Thioridazine 233-245 dopamine receptor D2 Homo sapiens 130-150 27398159-14 2016 CONCLUSION: Taken together, all the data in the present study suggested that the THIO plus MPA might act as the suppressor of tumor growth in ECa by inhibiting the PI3K/AKT signal transduction pathway, which was mediated by PRB, DRD2 and EGFR. Thioridazine 81-85 dopamine receptor D2 Homo sapiens 229-233 25832589-0 2015 Dopamine D2 receptor blocker thioridazine induces cell death in human uterine cervical carcinoma cell line SiHa. Thioridazine 29-41 dopamine receptor D2 Homo sapiens 0-20 25832589-1 2015 AIM: The aim of this study was to explore the correlation of dopamine D2 receptor (DRD2) and the development of uterine cervical cancer, and the effect of thioridazine (an antagonist of DRD2) on the SiHa cell line. Thioridazine 155-167 dopamine receptor D2 Homo sapiens 186-190 25832589-6 2015 In vitro, DRD2 blocker thioridazine treatment resulted in death of SiHa cells with the expression of DRD2 significantly regulated down (P < 0.05), and thioridazine significantly induced SiHa apoptosis (P = 0.016) and necrosis (P < 0.01). Thioridazine 23-35 dopamine receptor D2 Homo sapiens 10-14 25832589-6 2015 In vitro, DRD2 blocker thioridazine treatment resulted in death of SiHa cells with the expression of DRD2 significantly regulated down (P < 0.05), and thioridazine significantly induced SiHa apoptosis (P = 0.016) and necrosis (P < 0.01). Thioridazine 23-35 dopamine receptor D2 Homo sapiens 101-105 25832589-6 2015 In vitro, DRD2 blocker thioridazine treatment resulted in death of SiHa cells with the expression of DRD2 significantly regulated down (P < 0.05), and thioridazine significantly induced SiHa apoptosis (P = 0.016) and necrosis (P < 0.01). Thioridazine 154-166 dopamine receptor D2 Homo sapiens 10-14 25832589-4 2015 After 20-muM thioridazine treatment for 24 h, the protein level of DRD2 in SiHa cells was analyzed by Western blots, apoptosis was detected with the phosphatidylserine externalization and comet assay, and necrosis was detected by measuring high-mobility group box 1 protein (HMGB1). Thioridazine 13-25 dopamine receptor D2 Homo sapiens 67-71